Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 6
2004 5
2005 6
2006 4
2007 3
2008 9
2009 4
2010 1
2011 8
2012 6
2013 2
2014 2
2015 3
2016 2
2017 4
2018 6
2019 10
2020 12
2021 9
2022 10
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness of sodium-glucose cotransporter-2 inhibitors on the progression of chronic kidney disease in patients without diabetes, with and without albuminuria.
Nakhleh A, Abdul-Ghani M, Gazit S, Gross A, Livnat I, Greenbloom M, Yarden A, Khazim K, Shehadeh N, Melzer Cohen C. Nakhleh A, et al. Among authors: shehadeh n. Diabetes Obes Metab. 2024 Apr 28. doi: 10.1111/dom.15623. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38680053
Safety and Effectiveness of Sodium-Glucose Co-transporter 2 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes Mellitus Fasting during Ramadan: A Review.
Nakhleh A, Mazareeb J, Darawshi S, Masri A, Shehadeh N. Nakhleh A, et al. Among authors: shehadeh n. Clin Med Insights Endocrinol Diabetes. 2024 Mar 14;17:11795514241238058. doi: 10.1177/11795514241238058. eCollection 2024. Clin Med Insights Endocrinol Diabetes. 2024. PMID: 38495948 Free PMC article. Review.
Dapagliflozin or Saxagliptin in Pediatric Type 2 Diabetes.
Shehadeh N, Barrett T, Galassetti P, Karlsson C, Monyak J, Iqbal N, Tamborlane WV. Shehadeh N, et al. NEJM Evid. 2023 Dec;2(12):EVIDoa2300210. doi: 10.1056/EVIDoa2300210. Epub 2023 Oct 4. NEJM Evid. 2023. PMID: 38320500
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J; DINAMO Study Group. Laffel LM, et al. Lancet Diabetes Endocrinol. 2023 Mar;11(3):169-181. doi: 10.1016/S2213-8587(22)00387-4. Epub 2023 Feb 1. Lancet Diabetes Endocrinol. 2023. PMID: 36738751 Free PMC article. Clinical Trial.
107 results